- Previous Close
16.31 - Open
18.25 - Bid 19.32 x 200
- Ask 19.38 x 100
- Day's Range
18.24 - 20.18 - 52 Week Range
3.54 - 21.13 - Volume
11,164,190 - Avg. Volume
5,315,896 - Market Cap (intraday)
4.515B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
138.36 - EPS (TTM)
0.14 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.65
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
www.admabiologics.comRecent News: ADMA
View More
Performance Overview: ADMA
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADMA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADMA
View MoreValuation Measures
Market Cap
4.51B
Enterprise Value
4.57B
Trailing P/E
138.36
Forward P/E
28.49
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.65
Price/Book (mrq)
23.98
Enterprise Value/Revenue
13.83
Enterprise Value/EBITDA
67.47
Financial Highlights
Profitability and Income Statement
Profit Margin
10.53%
Return on Assets (ttm)
15.07%
Return on Equity (ttm)
20.77%
Revenue (ttm)
330.24M
Net Income Avi to Common (ttm)
34.79M
Diluted EPS (ttm)
0.14
Balance Sheet and Cash Flow
Total Cash (mrq)
88.24M
Total Debt/Equity (mrq)
75.10%
Levered Free Cash Flow (ttm)
43.77M
Research Analysis: ADMA
View MoreCompany Insights: ADMA
ADMA does not have Company Insights
Research Reports: ADMA
View MoreRaising target price to $22.00
ADMA BIOLOGICS INC has an Investment Rating of BUY; a target price of $22.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $20.00
ADMA BIOLOGICS INC has an Investment Rating of BUY; a target price of $20.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $22.00
ADMA BIOLOGICS INC has an Investment Rating of BUY; a target price of $22.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetRating increased to a BUY
ADMA BIOLOGICS INC has an Investment Rating of BUY; a target price of $27.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target